Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers

Clinical and Experimental Hypertension

Volumn 29, Issue 8, 2007, Pages 539-552

  Mignini, Fiorenzo ^a   Tomassoni, Daniele ^a   Traini, Enea ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Amlodipine; Besylate; Bioequivalence; Maleate; Sex differences

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE MALEATE; GENERIC DRUG; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE MEASUREMENT; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 36849033345     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960701744046     Document Type: Article

References (35)

1. Nissen D, ed. Mosby's Drug Consult. St. Louis, Mo.: Elsevier Science; 2003: III-157.
2. Hutchison TA, Shahan DR, eds. DRUGDEX System. Greenwood Village, Colorado: MICROMEDEX; 2003:115.
3. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol. 1994;73:2A-9A.
4. Salhanick S, Shannon MW. Management of calcium antagonist overdose. Drug Safety. 2003;26:65-79.
5. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
6. EMEA/CPMC opinion following an article 29 referral. International non-proprietary name: Amlodipine. London; 2004.
7. Park S, Chung N, Kwon J, Yoon JH, Kim YJ, Han DS, Kim HS. Results of a multicenter, eight-week, parallel-group, randomized, double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. Clin Ther. 2005;27:441-450.
8. New amlodipine (Amloc) product available in South Africa. Cardiovasc J S Afr. 2005;16:61.
9. Park JY, Kim KA, Lee GS, Park PW, Kim SL, Lee YS, Lee YW, Shin EK. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther. 2004;26:715-723.
10. Hong SJ, Ahn TH, Baek SH, Cho WH, Jeon HK, Kyun J, Yoon MH, Lee KJ, Lim DS. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, eight-week follow-up, noninferiority trial. Clin Ther. 2006;28:537-551.
11. European Agency for the Evaluation of Medical Products, Committee for Proprietary Medical Products. Good Clinical Practice: Consolidated Guideline CPMP/ICH/135/95. 1996 July 17.
12. Recepimento delle linee guida dell'U.E. di Buona Pratica Clinica per la esecuzione delle sperimentazioni cliniche dei medicinali. Gazzetta Ufficiale della Repubblica Italiana; 1997 Jun 15:139.
13. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22:21-25.
14. European Agency for the Evaluation of Medical Products, Committee for Proprietary Medical Products. Note for guidance on the investigation of bioavailability and bioequivalence. London; 2001.
15. Westlake W. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci. 1972;6:1340-1341.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm. 1987;15:657-680.
17. Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990;28:72-78.
18. Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;28:105-110.
19. Phillips KF. Power of the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm. 1990;18:137-144.
20. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker Inc; 1992.
21. Sauter R, Steinijans VW, Diletti E. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30:233-256.
22. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005;43:485-498.
23. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville, Md.: Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, March 2003.
24. Health Canada. Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part A: Oral Dosage Formulations Used for Systemic Effects. Ottawa, Ontario, Canada: Ministry of Health; 1992.
25. Japan National Institute of Health, Division of Drugs. Guideline for Bioequivalence Studies of Generic Drug Products. Tokyo: NIH Japan; 1997.
26. Medicines Control Council, Department of Health, Republic of South Africa. Registration of Medicines: Biostudies. Pretoria, South Africa: MCC; 2003.
27. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol. 1994;73:2A-9A.
28. van Zwieten PA. Amlodipine: an overview of its pharmacodynamic and pharmacokinetics properties. Clin Cardiol. 1994;17:3-6.
29. Godfraind T, Mennig D, Bravo G, Chalant C, Jaumin P. Inhibition by amlodipine of activity evoked in isolated human coronary arteries by endothelin, prostaglandin F2 alpha and depolarization. Am J Cardiol. 1989;64:58I-64I.
30. Pascual J. Hypertension control in the elderly with amlodipine. Curr Med Res Opin. 2000;16:33-36.
31. Nayler WG, Gu XH. Vascular and myocardial effects of amlodipine: An overview. Postgrad Med J 1991;67:S41-S43.
32. Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Crivelli F, Ismaili S, Uhr MR, La Commare P. Amlodipine bioequivalence achieved with a very sensitive liquid chromatography tandem mass spectrometric bioassay. Arzneimittelforschung. 2000;50:688-694.
33. Carvalho M, Oliveira CH, Mendes GD, Sucupira M, Moraes ME, De Nucci G. Amlodipine bioequivalence study: Quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos. 2001;22:383-390.
34. Rojanasthien N, Teekachunhatean S, Jakob K, Gaupp M, Arnold P, Chaichana N, Martin W. Bioequivalence study of generic amlodipine in healthy Thai male volunteers. Int J Clin Pharmacol Ther. 2004;42:330-335.
35. Abad-Santos F, Novalbos J, Galvez-Mugica MA, Gallego-Sandin S, Almeida S, Vallee F, Garcia AG. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res. 2005;51:445-452.